The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers

References

• Ambudkar SV, Dey S, Hrycyna CA, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–98
   PubMed Web of Science ®Google Scholar
• Bedada SK, Yakkanti SA, Neerati P. (2014). Resveratrol enhances the bioavailability of fexofenadine in healthy human male volunteers: involvement of P-glycoprotein inhibition. J Bioequiv Availab 6:158–63
   Google Scholar
• Brand W, Schutte ME, Williamson G, et al. (2006). Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 60:508–19
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, et al. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–71
   PubMed Web of Science ®Google Scholar
• Di Pietro A, Conseil G, Pérez-Victoria JM, et al. (2002). Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59:307–22
   PubMed Web of Science ®Google Scholar
• Drescher S, Schaeffeler E, Hitzl M, et al. (2002). MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526–34
   PubMed Web of Science ®Google Scholar
• Fromm MF. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69–74
   PubMed Web of Science ®Google Scholar
• Guo D, Zou J, Zhu Y, et al. (2010). Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. Biomed Chromatogr 24:335–41
   PubMed Web of Science ®Google Scholar
• Han Y, Guo D, Chen Y, et al. (2009). Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica 39:694–9
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Park JY. (2009). Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 65:609–14
   PubMed Web of Science ®Google Scholar
• Ling KH, Leeson GA, Burmaster SD, et al. (1995). Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631–6
   PubMed Web of Science ®Google Scholar
• Middleton E Jr, Kandaswami C, Theoharides TC. (2000). The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751
   PubMed Web of Science ®Google Scholar
• Neerati P, Bedada SK. (2015). Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. Pharmacol Rep 67:339–44
   PubMed Web of Science ®Google Scholar
• Niemi M, Kivisto KT, Hofmann U, et al. (2005). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602–4
   PubMed Web of Science ®Google Scholar
• Nozawa T, Imai K, Nezu J, et al. (2004). Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438–45
   PubMed Web of Science ®Google Scholar
• Pari L, Srinivasan S. (2010). Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Biomed Pharmacother 64:477–81
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Greenblatt DJ. (2002). Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 42:1269–74
   PubMed Web of Science ®Google Scholar
• Petri N, Tannergren C, Rungstad D, Lennernas H. (2004). Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 21:1398–404
   PubMed Web of Science ®Google Scholar
• Rajnarayana K, Reddy MS, Krishna DR. (2003). Diosmin pretreatment affects bioavailability of metronidazole. Eur J Clin Pharmacol 58:803–7
   PubMed Web of Science ®Google Scholar
• Rajnarayana K, Venkatesham A, Krishna DR. (2008). Influence of some bioflavonoids on the transport of nitrendipine. Drug Metabol Drug Interact 23:299–310
   PubMedGoogle Scholar
• Rajnarayana K, Venkatesham A, Krishna DR. (2007). Bioavailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers. Drug Metabol Drug Interact 22:165–74
   PubMedGoogle Scholar
• Rajnarayana K, Venkatesham A, Nagulu M, et al. (2008). Influence of diosmin pretreatment on the pharmacokinetics of chlorzoxazone in healthy male volunteers. Drug Metabol Drug Interact 23:311–21
   PubMedGoogle Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. (2008). Dose translation from animal to human studies revisited. FASEB J 22:659–61
   PubMed Web of Science ®Google Scholar
• Romano B, Pagano E, Montanaro V, et al. (2013). Novel insights into the pharmacology of flavonoids. Phytother Res 27:1588–96
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Mayer U, Wagenaar E, et al. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028–33
   PubMed Web of Science ®Google Scholar
• Shimizu M, Uno T, Sugawara K, Tateishi T. (2006). Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 61:538–44
   PubMed Web of Science ®Google Scholar
• Shon JH, Yoon YR, Hong WS, et al. (2005). Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78:191–201
   PubMed Web of Science ®Google Scholar
• Simpson K, Jarvis B. (2000). Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59:301–21
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Maeda K, et al. (2006). Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743–7
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–8
   PubMed Web of Science ®Google Scholar
• Uno T, Shimizu M, Sugawara K, Tateishi T. (2006). Lack of dose dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 34:1875–9
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Bourbeau M, Campbell P, et al. (2006). Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46:758–67
   PubMed Web of Science ®Google Scholar
• Wang X, Wolkoff AW, Morris ME. (2005). Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33:1666–72
   PubMed Web of Science ®Google Scholar
• Yamsani SK, Yamsani MR. (2014). Effect of silymarin pretreatment on the bioavailability of domperidone in healthy human volunteers. Drug Metabol Drug Interact 29:261–7
   PubMedGoogle Scholar
• Yoo HH, Lee M, Chung HJ, et al. (2007). Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem 55:7620–5
   PubMed Web of Science ®Google Scholar
• Yumoto R, Murakami T, Nakamoto Y, et al. (1999). Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149–55
   PubMed Web of Science ®Google Scholar
• Zhang S, Morris ME. (2003). Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258–67
   PubMed Web of Science ®Google Scholar